Skip to main content

Table 1 USP39 expression and patient characteristics of Zhao Renal dataset

From: USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1

 

No. Pts

No. USP39

p Value

Low

High

Overall: n (%)

176 (100.0)

88 (50.0)

88 (50.0)

0.286a

 Male

101 (57.4)

47 (26.7)

54 (30.7)

 Female

75 (42.6)

41 (23.3)

34 (19.3)

Mean patient age, y (range)

65.2 (34–85)

63.7(42–85)

66.6 (34–85)

< 0.000b

WHO performance status: n (%)

   

0.146a

 0

65 (36.9)

29 (16.5)

36 (20.5)

 1

63 (35.8)

35 (19.9)

28 (15.9)

 2

37 (21.0)

16 (9.1)

21 (11.9)

 3

10 (5.7)

8 (4.5)

2 (1.1)

 4

1 (0.6)

0 (0.0)

1 (0.6)

TNM stage: n (%)

   

0.919a

 I

49 (27.8)

25 (14.2)

24 (13.6)

 II

29 (16.5)

16 (9.1)

13 (7.4)

 III

40 (22.7)

19 (10.8)

21 (11.9)

 IV

58 (33.0)

28 (15.9)

30 (17.0)

Fuhrman grade: n (%)

   

0.726a

 1

9 (5.1)

6 (3.4)

3 (1.7)

 2

34 (19.3)

18 (10.2)

16 (9.1)

 3

93 (52.8)

45 (25.6)

48 (27.3)

 4

40 (22.7)

19 (10.8)

21 (11.9)

Patient outcome: n (%)

   

0.008a

 Died

111 (63.1)

47 (21.6)

64 (27.3)

 Alive

65 (36.9)

41 (4.0)

24 (1.1)

Median OS, mo (95% CI)

39 (33.4–44.6)

59 (14.1–103.9)

35 (23.0–47.0)

0.006c

  1. Analysis of USP39 in the ONCOMINE gene database. The expression level of USP39 was positively correlated with the survival rate of renal cancer patients
  2. aChi-square test
  3. bWilcoxon rank sum test
  4. cLog rank test